Jacqualyn A Fouse Incyte Corp (INCY) insider trading activity

Jacqualyn A Fouse is Director of INCYTE CORP. Currently has a direct ownership of 16,808 shares of INCY, which is worth approximately $963,602. The most recent transaction as insider was on Jun 12, 2024, when has been sold 2,830 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 16.8K

20.25% 3M change

20.25% 12M change

Total Value Held $963,602

JACQUALYN A FOUSE Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 12 2024	BUY Grant, award, or other acquisition	-	2,830 Added 14.41%	16,808 Common Stock
Jun 14 2023	BUY Grant, award, or other acquisition	-	2,505 Added 15.2%	13,978 Common Stock
Dec 30 2022	BUY Grant, award, or other acquisition	$20,240 $80.32 p/Share	252 Added 2.15%	11,473 Common Stock
Sep 30 2022	BUY Grant, award, or other acquisition	$19,392 $66.64 p/Share	291 Added 2.53%	11,221 Common Stock
Jun 30 2022	BUY Grant, award, or other acquisition	$20,892 $75.97 p/Share	275 Added 2.45%	10,930 Common Stock
Jun 15 2022	BUY Grant, award, or other acquisition	-	2,144 Added 16.75%	10,655 Common Stock
Mar 31 2022	BUY Grant, award, or other acquisition	$22,238 $79.42 p/Share	280 Added 3.19%	8,511 Common Stock

Dec 31 2021	BUY Grant, award, or other acquisition	$21,213 $73.4 p/Share	289 Added 3.39%	8,231 Common Stock
Sep 30 2021	BUY Grant, award, or other acquisition	$18,639 $68.78 p/Share	271 Added 3.3%	7,942 Common Stock
Jun 30 2021	BUY Grant, award, or other acquisition	$20,023 $84.13 p/Share	238 Added 3.01%	7,671 Common Stock
May 26 2021	BUY Grant, award, or other acquisition	-	1,923 Added 20.55%	7,433 Common Stock
Mar 31 2021	BUY Grant, award, or other acquisition	$20,399 $81.27 p/Share	251 Added 4.36%	5,510 Common Stock
Dec 31 2020	BUY Grant, award, or other acquisition	$20,614 $86.98 p/Share	237 Added 4.31%	5,259 Common Stock
Sep 30 2020	BUY Grant, award, or other acquisition	$19,653 $89.74 p/Share	219 Added 4.18%	5,022 Common Stock

Also insider at

AGIO

AGIOS PHARMACEUTICALS, INC. Healthcare

Director

JAF